Although it “has stirred significant controversy in recent years,” the Congressional Research Service policy of restricting direct dissemination of its products to members of Congress is well-founded, argued CRS director Daniel P. Mulhollan in a lengthy internal memorandum (pdf) last month.
“The reasons for limiting public distribution of our work can be summarized as follows,” he wrote.
“First, there is a danger that placing CRS in an intermediate position [between Congress and the public] would threaten the dialog on policy issues between Members and their constituents.”
“Second, the current judicial … perception of CRS as ‘adjunct staff’ of the Congress might be altered if CRS were seen as speaking directly to the public, putting at risk Speech or Debate Clause constitutional protections afforded the confidential work performed by this agency.”
“And third, if CRS products were routinely disseminated broadly to the public, over time these products might come to be written with a large public audience in mind and would no longer be focused solely on congressional needs.”
A copy of Director Mulhollan’s seven page memorandum on “Access to CRS Reports,” dated April 18, 2007, was obtained by Secrecy News and is available here.
The arguments detailed by Mr. Mulhollan seem singularly unpersuasive to an outsider. CRS is not being called upon to mediate between Congress and the public or to engage in a public dialog on policy issues. Rather, proponents of broader dissemination are simply asking for the same public access that commercial vendors of CRS reports already enjoy.
The transition to a clean energy future and diversified sources of energy requires a fundamental shift in how we produce and consume energy across all sectors of the U.S. economy.
A deeper understanding of methane could help scientists better address these impacts – including potentially through methane removal.
While it is reasonable for governments to keep the most sensitive aspects of nuclear policies secret, the rights of their citizens to have access to general knowledge about these issues is equally valid so they may know about the consequences to themselves and their country.
Advancing the U.S. leadership in emerging biotechnology is a strategic imperative, one that will shape regional development within the U.S., economic competitiveness abroad, and our national security for decades to come.